Biotech News
Aplagon Secures €7M to Advance Phase 2a Trial for Thrombo-Inflammatory Drug APAC
Aplagon, a clinical-stage biopharmaceutical company developing APAC, a heparin proteoglycan mimetic for thrombo-inflammatory diseases, has secured €7 million in new financing. The round was led by Nordic venture capital firm Fåhraeus Startup and Growth AB (FSG) and the European Innovation
5 February 2025